💊 Arzneimittel A-Z 🧬 Targets 🛠 Werkzeuge 📚 Leitfäden
Alle Arzneimittel Arzneimittelklassen Therapeutische Bereiche Nebenwirkungen
Leitfäden Glossar Zeitleiste
Vergleiche Arzneimittelreisen Arzneimittel-Wirkstoffgruppen
🇺🇸 English 🇰🇷 한국어 🇯🇵 日本語 🇨🇳 中文简体 🇪🇸 Español 🇧🇷 Português 🇮🇳 हिन्दी 🇸🇦 العربية 🇫🇷 Français 🇷🇺 Русский 🇩🇪 Deutsch 🇹🇷 Türkçe 🇻🇳 Tiếng Việt 🇮🇩 Bahasa Indonesia 🇹🇭 ไทย

Zonisamide

CHEMBL750 Phase 4 Zugelassen Small molecule
Half-Life
—
Bioavailability
—
Protein Binding
—
Molecular Weight
212.2 g/mol
LogP
0.2
Phase
4

This anticonvulsant medication is used as an add-on treatment for partial seizures in adults with epilepsy and is also used off-label as an adjunct in Parkinson's disease. It works through multiple mechanisms including blocking sodium and calcium channels in the brain to reduce abnormal electrical activity. It can cause kidney stones, so adequate hydration is important, and it should be avoided in patients with sulfonamide allergies.

Molekularmasse

212,2300 g/mol

LogP

0,20

TPSA

94,60 Ų

Lipinski-Regel der Fünf

Bestanden

Therapeutische Bereiche

Epilepsy Migraine Schizophrenia Bipolar Disorder Obesity Hypertension

Pharmacokinetics (PK)

Pharmacodynamics (PD)

2D-Struktur

SVG PNG

Cite this structure


                        

                            
                            
                        

                    

                


                
                

                    

                    

                        
Embed this structure

                        

                        

                            
                            
                        

                    

                

                

                
                

                    
SMILES

                    
NS(=O)(=O)Cc1noc2ccccc12

                

                

                
                

                    
InChI

                    
InChI=1S/C8H8N2O3S/c9-14(11,12)5-7-6-3-1-2-4-8(6)13-10-7/h1-4H,5H2,(H2,9,11,12)

                

                

                

                    
                    

                        
Molecular Formula

                        
C8H8N2O3S

                    

                    
                    

                        
HBD / HBA

                        
1 / 5

                    

                    
                    

                        
Rotierbare Bindungen

                        
2

                    

                    
                    
                    

                        
Schwere Atome

                        
14

                    

                    
                

            


            
            

                
                


    
    
        
    
    
    
No targets recorded

    
    
Target interaction data is not yet available for this drug.

    



                
            


            
            

                
                


    
    
        
    
    
    
No interactions recorded

    
    
Drug interaction data is not yet available for this compound.

    



                
            


            
            

                
                


    
    
        
    
    
    
No side effects recorded

    
    
Side effect data is not yet available for this drug.

    



                
            


            
            
            

                
Häufig gestellte Fragen

                

                    
                    

                        
                        

                            
This anticonvulsant medication is used as an add-on treatment for partial seizures in adults with epilepsy and is also used off-label as an adjunct in Parkinson's disease. It works through multiple mechanisms including blocking sodium and calcium channels in the brain to reduce abnormal electrical activity. It can cause kidney stones, so adequate hydration is important, and it should be avoided in patients with sulfonamide allergies.

                        

                    

                    

                    

                    

                    

                    

                        
                        

                            
Yes, Zonisamide is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

                        

                    

                

            

            

            
            

            
            

            
            
{# References & Data Sources section for drug detail pages.
   Renders standard pharmacological database links plus the drug's data_sources field. #}


    
References & Data Sources

    
    
        
        
  • 
            
            
                ChEMBL — European Bioinformatics Institute (EBI).
                CHEMBL750.
                Open-access bioactivity database.
            
        
    • 
        
        
        
  • 
            
            
                PubChem — National Center for Biotechnology Information (NCBI).
                CID 5734.
                Chemical information database.
            
        
    • 
        
        
        
        
    

    
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-28.




        


        
        
    


    



    
Medizinischer Haftungsausschluss

    

        This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.
    

    

        Data sources:
        ChEMBL,
        PubChem,
        DailyMed.